Asunercept Treatment COVID-19: Phase II clinical trials have been conducted in Europe and Russia.

Apogenix, !---- a biopharmaceutical company, announced today that it has begun Phase II clinical trials in Spain and Russia for the treatment of COVID-19.ASUNCTIS trial is a multicenter, randomized, controlled, open-label trial designed to assess the efficacy and safety of asunercept in treating patients with severe COVID-19 disease.published data show that CD95 ligand (CD95L) - a sunercept target - plays a role in inducing life-threatening lymphocyte reduction and pulmonary epithelial damage.CD95 molecule and its ligand CD95 matching also play an important role in the signaling process of apoptosis.by blocking CD95L, asunercept can reduce these complications in patients with COVID-19.the ASUNCTIS trial will have four treatment groups to compare the effectiveness and safety of three different doses of asunercept combined standard care with standard care, and the ASUNCTIS trial will recruit about 400 patients. The main endpoint ofis the clinical performance scale proposed by the World Health Organization.secondary endpoints include the need for mechanical ventilation, length of hospital stay, and mortality rates on days 15 and 29..